Hearing News Watch

LONDON, UNITED KINGDOM — The National Institute for Health and Care Excellence (NICE) has recommended a new treatment aimed at preventing and reducing hearing loss in patients undergoing cisplatin chemotherapy. This marks a significant step forward in addressing a common and often debilitating side effect of a widely used cancer treatment. Cisplatin is a chemotherapy drug commonly administered to treat various

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in therapies to restore, treat, and prevent hearing loss disorders, has announced promising data from the first two patients treated in the Audiogene Phase 1/2 clinical trial evaluating SENS-501. This trial focuses on infants and toddlers aged 6 to 31 months who suffer from a specific form of

EDEN PRAIRIE, MINNESOTA – Starkey has announced that its Founder and Chairman, William F. Austin, has been awarded an honorary degree from Kenyatta University in recognition of his groundbreaking contributions to hearing healthcare and his unwavering commitment to serving disadvantaged communities in Africa and throughout the world. Bill Austin’s vision and generosity have touched millions of lives around the globe.

SOMERSET, NEW JERSEY — On December 6th, Oticon President Gary Rosenblum and Mariann Cadieu, Executive Director of the Oticon Hearing Foundation, visited Mary’s Place by the Sea—a respite home dedicated to supporting women battling cancer. The facility received a generous donation raised through the dedicated efforts of Demant staff volunteers and sales promotions. During their visit, the team toured the

Hearing loss, a condition affecting millions globally, often extends beyond the obvious symptoms captured by standard audiograms. Up to 10% of patients experiencing hearing difficulties have conditions that remain undiagnosed through conventional clinical tests. Addressing this unmet need, researchers at the University of Pittsburgh have developed a groundbreaking diagnostic tool for detecting hidden hearing pathologies, offering new hope for improved

SEATTLE, WASHINGTON — Sound Pharmaceuticals announced today that its pivotal Phase 3 clinical trial evaluating SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of Meniere’s Disease (STOPMD-3) successfully met its co-primary efficacy endpoints. These results demonstrate significant improvements in hearing loss and speech discrimination. Meniere’s disease (MD) is an inner ear disorder that causes fluctuating hearing loss, tinnitus, and

The European Union of Hearing Aid Acousticians (EUHA) has announced the call for papers for its upcoming Digital EUHA Spring Conference, scheduled to begin on March 28, 2025. The conference, an established event in the hearing care community, attracts both members and non-members, including a significant number of international participants. The event will feature live presentations on the opening day,

A new USC Stem Cell study published in the Proceedings of the National Academy of Sciences (PNAS), reveals the genetic mechanisms that enable fish and lizards to regenerate their hearing after injury. By identifying key gene regulators and DNA control elements, the research offers valuable insights into sensory cell regeneration, paving the way for potential therapeutic strategies to restore hearing

MONTPELLIER, FRANCE – Cilcare, a biotechnology company specializing in auditory sciences, has announced the completion of its €40 million Series A funding round, with €21 million secured in the latest phase. This milestone was achieved with the participation of new investors, including SHIONOGI & CO., LTD., and Sprim Global Investments Pte. Ltd., as well as existing backers such as Sofilaro,

GAINESVILLE, FLORIDA – Neurotone AI, a pioneer in aural rehabilitation and creator of Lace AI Pro, has announced a definitive agreement to acquire Amptify, a leading digital hearing healthcare platform developed at Washington University in St. Louis School of Medicine. The transaction, expected to close by the end of 2024, is subject to customary closing conditions. This acquisition aligns with